Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia

Blood

Volumn 124, Issue 3, 2014, Pages 453-462

  Rajasagi, Mohini ^a   Shukla, Sachet A ^a,b   Fritsch, Edward F ^a,b   Keskin, Derin B ^a   DeLuca, David ^a,b   Carmona, Ellese ^c   Zhang, Wandi ^a   Sougnez, Carrie ^b   Cibulskis, Kristian ^b   Sidney, John ^d   Stevenson, Kristen ^a   Ritz, Jerome ^a,c   Neuberg, Donna ^a   Brusic, Vladimir ^a   Gabriel, Stacey ^b   Lander, Eric S ^b   Getz, Gad ^b,e   Hacohen, Nir ^b,c   Wu, Catherine J ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD40 LIGAND; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; MESSENGER RNA; MICRORNA 143; T LYMPHOCYTE RECEPTOR;

ALLELE; ALTERNATIVE RNA SPLICING; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE RELEASE; FRAMESHIFT MUTATION; HUMAN; MELANOMA; MEMORY T LYMPHOCYTE; MISSENSE MUTATION; PRIORITY JOURNAL; SOMATIC MUTATION; T LYMPHOCYTE;

ANTIGENS, NEOPLASM; CANCER VACCINES; EPITOPES, T-LYMPHOCYTE; EXOME; FEMALE; HLA ANTIGENS; HUMANS; IMMUNOLOGIC MEMORY; INDIVIDUALIZED MEDICINE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MUTATION; PROTEIN BINDING; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84904472602     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-567933     Document Type: Article

References (62)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
2. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443- 2454.
3. Taneja SS. Re: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. J Urol. 2012;188(6):2149.
4. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480-489.
5. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol. 2006;24:175-208.
6. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10(9):909-915. (Pubitemid 39273730)
7. van der Burg SH, Melief CJ. Therapeutic vaccination against human papilloma virus induced malignancies. Curr Opin Immunol. 2011;23(2):252-257.
8. Nedergaard MK, Hedegaard CJ, Poulsen HS. Targeting the epidermal growth factor receptor in solid tumor malignancies. BioDrugs. 2012;26(2):83-99.
9. Baskar S, Kobrin CB, Kwak LW. Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes. J Clin Invest. 2004;113(10):1498-1510. (Pubitemid 39071706)
10. Garraway LA, Lander ES. Lessons from the cancer genome. Cell. 2013;153(1):17-37.
11. Hacohen N, Fritsch EF, Carter TA, Lander ES, Wu CJ. Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunol Res. 2013;1(1):11-15.
12. Heemskerk B, Kvistborg P, Schumacher TN. The cancer antigenome. EMBO J. 2013;32(2):194-203.
13. Sensi M, Anichini A. Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy. Clin Cancer Res. 2006;12(17):5023-5032. (Pubitemid 44453327)
14. Parmiani G, De Filippo A, Novellino L, Castelli C. Unique human tumor antigens: immunobiology and use in clinical trials. J Immunol. 2007;178(4):1975-1979. (Pubitemid 46233392)
15. Mandelboim O, Vadai E, Fridkin M, et al. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat Med. 1995;1(11):1179-1183.
16. Lennerz V, Fatho M, Gentilini C, et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005;102(44):16013-16018. (Pubitemid 41552859)
17. Zhou J, Dudley ME, Rosenberg SA, Robbins PF. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother. 2005;28(1):53-62. (Pubitemid 40075938)
18. van Rooij N, van Buuren MM, Philips D, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol. 2013;31(32):e439-e442.
19. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546-1558.
20. Lin HH, Ray S, Tongchusak S, Reinherz EL, Brusic V. Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research. BMC Immunol. 2008;9:8.
21. Zhang GL, Ansari HR, Bradley P, et al. Machine learning competition in immunology - Prediction of HLA class I binding peptides. J Immunol Methods. 2011;374(1-2):1-4.
22. Dores GM, Anderson WF, Curtis RE, et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol. 2007;139(5):809-819. (Pubitemid 350115721)
23. Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10(1):37-50.
24. Del Giudice I, Chiaretti S, Tavolaro S, et al. Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases. Blood. 2009;114(3):638-646.
25. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152(4):714-726.
26. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365(26):2497-2506.
27. Burkhardt UE, Hainz U, Stevenson K, et al. Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest. 2013;123(9):3756-3765.
28. Sidney J, Southwood S, Oseroff C, del Guercio MF, Sette A, Grey HM. Measurement of MHC/peptide interactions by gel filtration. Curr Protoc Immunol; 2001. Chapter 18:Unit 18-13.
29. Cai A, Keskin DB, DeLuca DS, et al. Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients. Clin Cancer Res. 2012;18(20):5761-5772.
30. Jäger E, Gnjatic S, Nagata Y, et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A. 2000;97(22):12198- 12203.
31. Hardwick N, Buchan S, Ingram W, et al. An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide. Cancer Immun. 2013;13:16.
32. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214-218.
33. Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213-219.
34. Lundegaard C, Lund O, Nielsen M. Prediction of epitopes using neural network based methods. J Immunol Methods. 2011;374(1-2):26-34.
35. Sette A, Vitiello A, Reherman B, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol. 1994;153(12):5586-5592. (Pubitemid 24377694)
36. Fritsch ED, Rajasagi M, Ott PA, Brusic V, Hacohen N, Wu CJ. HLA-binding properties of tumor neoepitopes in humans [published online ahead of print March 3, 2014]. Cancer Immunol Res.
37. Collin GB, Cyr E, Bronson R, et al. Alms1-disrupted mice recapitulate human Alström syndrome. Hum Mol Genet. 2005;14(16):2323-2333. (Pubitemid 41417995)
38. Collin GB, Marshall JD, Ikeda A, et al. Mutations in ALMS1 cause obesity, type 2 diabetes and neurosensory degeneration in Alström syndrome. Nat Genet. 2002;31(1):74-78.
39. Liu HJ, Tan YR, Li ML, Liu C, Xiang Y, Qin XQ. Cloning of a novel protein interacting with BRS-3 and its effects in wound repair of bronchial epithelial cells. PLoS ONE. 2011;6(8):e23072.
40. Forbes SA, Tang G, Bindal N, et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 2010;38(Database issue):D652-D657.
41. Cai C, Rajaram M, Zhou X, et al. Activation of multiple cancer pathways and tumor maintenance function of the 3q amplified oncogene FNDC3B. Cell Cycle. 2012;11(9):1773-1781.
42. Shukla SA, Rajasagi M, Dixon PM, et al. Sensitive detection of somatic class I HLA mutations using exome capture sequencing. (Submitted)
43. Ene CI, Fine HA. Many tumors in one: a daunting therapeutic prospect. Cancer Cell. 2011;20(6):695-697.
44. Longo DL. Tumor heterogeneity and personalized medicine. N Engl J Med. 2012;366(10):956-957.
45. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306-313.
46. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973-977.
47. Robbins PF, Lu YC, El-Gamil M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19(6):747-752.
48. Lu YC, Yao X, Li YF, et al. Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J Immunol. 2013;190(12):6034-6042.
49. Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014;344(6184):641-645.
50. Brown SD, Warren RL, Gibb EA, et al. Neoantigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 2014;24(5):743-750.
51. Castle JC, Kreiter S, Diekmann J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 2012;72(5):1081-1091.
52. Dubey P, Hendrickson RC, Meredith SC, et al. The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J Exp Med. 1997;185(4):695-705. (Pubitemid 27098154)
53. Matsushita H, Vesely MD, Koboldt DC, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012;482(7385):400-404.
54. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer. 2004;4(5):371-380. (Pubitemid 38579483)
55. Nishida T, Hudecek M, Kostic A, et al. Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia. Clin Cancer Res. 2009;15(14):4759-4768.
56. Zhang W, Choi J, Zeng W, et al. Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion. Clin Cancer Res. 2010;16(10):2729-2739.
57. Rammensee HG, Singh-Jasuja H. HLA ligandome tumor antigen discovery for personalized vaccine approach. Expert Rev Vaccines. 2013;12(10):1211-1217.
58. Stickel JS, Weinzierl AO, Hillen N, et al. HLA ligand profiles of primary renal cell carcinoma maintained in metastases. Cancer Immunol Immunother. 2009;58(9):1407-1417.
59. Neumann A, Hörzer H, Hillen N, et al. Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer. Cancer Immunol Immunother. 2013;62(9):1485-1497.
60. Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity. 1996;4(6):565-571. (Pubitemid 26233310)
61. Carter SL, Cibulskis K, Helman E, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012;30(5):413-421.
62. DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature. 2012;482(7385):405-409.